20,000 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Bamco Inc. NY

Bamco Inc. NY purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 20,000 shares of the company's stock, valued at approximately $2,293,000.

A number of other institutional investors and hedge funds have also made changes to their positions in KYMR. GAMMA Investing LLC increased its stake in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company's stock worth $52,000 after purchasing an additional 98 shares during the period. US Bancorp DE grew its holdings in shares of Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company's stock valued at $106,000 after purchasing an additional 166 shares in the last quarter. Glenmede Trust Co. NA grew its holdings in shares of Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company's stock valued at $565,000 after purchasing an additional 235 shares in the last quarter. Cetera Investment Advisers increased its stake in Kymera Therapeutics by 7.5% during the 1st quarter. Cetera Investment Advisers now owns 3,602 shares of the company's stock worth $300,000 after buying an additional 252 shares during the period. Finally, Larson Financial Group LLC increased its stake in Kymera Therapeutics by 36.9% during the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company's stock worth $83,000 after buying an additional 287 shares during the period.

Analyst Ratings Changes

KYMR has been the topic of a number of recent research reports. Barclays upped their price objective on Kymera Therapeutics from $133.00 to $139.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. BTIG Research reiterated a "buy" rating and issued a $134.00 target price on shares of Kymera Therapeutics in a report on Thursday, June 25th. Loop Capital set a $97.00 target price on Kymera Therapeutics in a research note on Monday, June 8th. Royal Bank Of Canada downgraded Kymera Therapeutics from an "outperform" rating to a "sector perform" rating and upped their price target for the stock from $106.00 to $115.00 in a report on Monday, July 13th. Finally, Truist Financial increased their price target on Kymera Therapeutics from $116.00 to $136.00 and gave the company a "buy" rating in a research report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics has an average rating of "Moderate Buy" and an average price target of $127.17.

Kymera Therapeutics Trading Down 4.2%

KYMR stock opened at $120.23 on Friday. Kymera Therapeutics, Inc. has a twelve month low of $39.84 and a twelve month high of $130.05. The company's 50 day moving average is $112.23 and its two-hundred day moving average is $93.44. The stock has a market cap of $10.00 billion, a P/E ratio of -37.11 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.09. The firm had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company's revenue was up 465.2% on a year-over-year basis. During the same period last year, the firm posted ($0.95) EPS. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the company's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the completion of the sale, the director directly owned 461,794 shares of the company's stock, valued at $50,557,207.12. This represents a 6.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the sale, the chief financial officer directly owned 244,883 shares of the company's stock, valued at $28,151,749.68. The trade was a 23.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,587,629 shares of company stock worth $386,183,782 over the last 90 days. Company insiders own 15.98% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source